Back to Search
Start Over
Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption
- Source :
- Lee, W S, Kristensen, A B, Rasmussen, T A, Tolstrup, M, Østergaard, L J, Søgaard, O S, Wines, B D, Hogarth, P M, Reynaldi, A, Davenport, M P, Emery, S, Amin, J, Cooper, D A, Kan, V L, Fox, J, Gruell, H, Parsons, M S & Kent, S J 2017, ' Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption ', Journal of Virology . https://doi.org/10.1128/JVI.00603-17
- Publication Year :
- 2017
-
Abstract
- There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on long-term antiretroviral therapy (ART) and may not be sufficient to eliminate reactivated latently infected cells. It is not known whether reactivation from latency with latency-reversing agents (LRAs) could provide sufficient antigenic stimulus to boost HIV-1-specific ADCC. We found that treatment with the LRA panobinostat or a short analytical treatment interruption (ATI), 21 to 59 days, was not sufficient to stimulate an increase in ADCC-competent antibodies, despite viral rebound in all subjects who underwent the short ATI. In contrast, a longer ATI, 2 to 12 months, among subjects enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) trial robustly boosted HIV-1 gp120-specific Fc receptor-binding antibodies and ADCC against HIV-1-infected cells in vitro . These results show that there is a lag between viral recrudescence and the boosting of ADCC antibodies, which has implications for strategies toward eliminating latently infected cells. IMPORTANCE The “shock and kill” HIV-1 cure strategy aims to reactivate HIV-1 expression in latently infected cells and subsequently eliminate the reactivated cells through immune-mediated killing. Several latency reversing agents (LRAs) have been examined in vivo , but LRAs alone have not been able to achieve HIV-1 remission and prevent viral rebound following analytical treatment interruption (ATI). In this study, we examined whether LRA treatment or ATI can provide sufficient antigenic stimulus to boost HIV-1-specific functional antibodies that can eliminate HIV-1-infected cells. Our study has implications for the antigenic stimulus required for antilatency strategies and/or therapeutic vaccines to boost functional antibodies and assist in eliminating the latent reservoir.
- Subjects :
- Adult
Male
0301 basic medicine
Indoles
Time Factors
Immunology
HIV Infections
Adaptive Immunity
HIV Antibodies
Stimulus (physiology)
Hydroxamic Acids
Microbiology
03 medical and health sciences
chemistry.chemical_compound
Antigen
In vivo
Virology
Panobinostat
Journal Article
Humans
Antibody-dependent cell-mediated cytotoxicity
biology
Antibody-Dependent Cell Cytotoxicity
virus diseases
Middle Aged
Acquired immune system
In vitro
030104 developmental biology
Anti-Retroviral Agents
chemistry
Insect Science
HIV-1
biology.protein
Pathogenesis and Immunity
Female
Antibody
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Lee, W S, Kristensen, A B, Rasmussen, T A, Tolstrup, M, Østergaard, L J, Søgaard, O S, Wines, B D, Hogarth, P M, Reynaldi, A, Davenport, M P, Emery, S, Amin, J, Cooper, D A, Kan, V L, Fox, J, Gruell, H, Parsons, M S & Kent, S J 2017, ' Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption ', Journal of Virology . https://doi.org/10.1128/JVI.00603-17
- Accession number :
- edsair.doi.dedup.....2f9c6040897dde0dce98610d2b82aea9
- Full Text :
- https://doi.org/10.1128/JVI.00603-17